Use of growth factors for the treatment of Parkinson’s disease

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2010-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1586/ern.10.55PMID 20518608
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone

  2010cited by this paper
• Granulocyte–macrophage colony‐stimulating factor promotes survival of dopaminergic neurons in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced murine Parkinson’s disease model

  2009cited by this paper
• Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's Disease

  2009cited by this paper
• Caloric Restriction and Aging: Studies in Mice and Monkeys

  2009cited by this paper
• Retinal pigment epithelial cells secrete neurotrophic factors and synthesize dopamine: possible contribution to therapeutic effects of RPE cell transplantation in Parkinson's disease

  2009cited by this paper
• Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease.

  2009cited by this paper
• Amino acid imbalance explains extension of lifespan by dietary restriction in Drosophila

  2009cited by this paper
• A Neuroprotective Function for the Hematopoietic Protein Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)

  2008cited by this paper
• Absolute requirement of GDNF for adult catecholaminergic neuron survival

  2008cited by this paper
• Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.

  2008cited by this paper
• Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis

  2008cited by this paper
• Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease.

  2008cited by this paper
• Spheramine for treatment of Parkinson’s disease

  2008cited by this paper
• Complete Spinal Cord Injury Treatment Using Autologous Bone Marrow Cell Transplantation and Bone Marrow Stimulation with Granulocyte Macrophage‐Colony Stimulating Factor: Phase I/II Clinical Trial

  2007cited by this paper
• GM-CSF inhibits apoptosis of neural cells via regulating the expression of apoptosis-related proteins.

  2007cited by this paper
• Striatal delivery of CERE‐120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys

  2007cited by this paper
• Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo

  2007cited by this paper
• Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors.

  2007cited by this paper
• The physiological and pharmacological role of basic fibroblast growth factor in the dopaminergic nigrostriatal system.

  2007cited by this paper
• AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease.

  2007cited by this paper
• Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease.

  2007cited by this paper
• Fibroblast Growth Factor (FGF)-2 and FGF Receptor 3 Are Required for the Development of the Substantia Nigra, and FGF-2 Plays a Crucial Role for the Rescue of Dopaminergic Neurons after 6-Hydroxydopamine Lesion

  2007cited by this paper
• RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals

  2007cited by this paper
• Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease

  2006cited by this paper
• Prevention of onset of Parkinson’s disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson’s disease

  2006cited by this paper
• Retinal pigment epithelial cell transplantation could provide trophic support in Parkinson's disease: results from an in vitro model system.

  2006cited by this paper
• Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys

  2006cited by this paper
• Delayed GM‐CSF treatment stimulates axonal regeneration and functional recovery in paraplegic rats via an increased BDNF expression by endogenous macrophages

  2006cited by this paper
• Granulocyte‐colony stimulating factor is neuroprotective in a model of Parkinson's disease

  2006cited by this paper
• Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease

  2006cited by this paper
• Recombinant human granulocyte colony‐stimulating factor protects against MPTP‐induced dopaminergic cell death in mice by altering Bcl‐2/Bax expression levels

  2006cited by this paper
• Genetics of Parkinson disease: paradigm shifts and future prospects

  2006cited by this paper
• The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis.

  2005cited by this paper
• Brain-Derived Neurotrophic Factor Is Required for the Establishment of the Proper Number of Dopaminergic Neurons in the Substantia Nigra Pars Compacta

  2005cited by this paper
• Neurorescue effects of VEGF on a rat model of Parkinson's disease.

  2005cited by this paper
• Glial cell line–derived neurotrophic factor induces neuronal sprouting in human brain

  2005cited by this paper
• The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model.

  2005cited by this paper
• The yin and yang of neurotrophin action

  2005cited by this paper
• Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.

  2005cited by this paper
• Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease

  2005cited by this paper
• Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of α‐synuclein in the substantia nigra

  2005cited by this paper
• Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study

  2005cited by this paper
• New roles for VEGF in nervous tissue--beyond blood vessels.

  2004cited by this paper
• Enhanced survival, reinnervation, and functional recovery of intrastriatal dopamine grafts co-transplanted with Schwann cells overexpressing high molecular weight FGF-2 isoforms.

  2004cited by this paper
• Localized striatal delivery of GDNF as a treatment for Parkinson disease

  2004cited by this paper
• Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease

  2004cited by this paper
• Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease

  2004cited by this paper
• Complications of a trophic xenotransplant approach in parkinsonian monkeys.

  2003cited by this paper
• PEDF: a multifaceted neurotrophic factor

  2003cited by this paper
• Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

  2003cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD

  2003cited by this paper
• Neuroprotective Effect of Granulocyte Colony–Stimulating Factor After Focal Cerebral Ischemia

  2003cited by this paper
• Parkinson's Disease Mechanisms and Models

  2003cited by this paper
• Glial Cell Line-Derived Neurotrophic Factor Increases Stimulus-Evoked Dopamine Release and Motor Speed in Aged Rhesus Monkeys

  2003cited by this paper
• Safety and Efficacy of Pegfilgrastim in Patients Receiving Myelosuppressive Chemotherapy

  2003cited by this paper
• Angiogenic and neurotrophic effects of vascular endothelial growth factor (VEGF165): studies of grafted and cultured embryonic ventral mesencephalic cells.

  2003cited by this paper
• Exacerbated status epilepticus and acute cell loss, but no changes in epileptogenesis, in mice with increased brain-derived neurotrophic factor signaling.

  2003cited by this paper
• MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons.

  2003cited by this paper
• Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: a potential new cell therapy for Parkinson's disease.

  2003cited by this paper
• Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF‐producing cells in a rat model of Parkinson's disease

  2002cited by this paper
• The GDNF family: Signalling, biological functions and therapeutic value

  2002cited by this paper
• Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy.

  2002cited by this paper
• Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1–3 of angiostatin reduce retinal neovascularization

  2002cited by this paper
• G-CSF Therapy of Ongoing Experimental Allergic Encephalomyelitis Via Chemokine- and Cytokine-Based Immune Deviation

  2002cited by this paper
• Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration.

  2002cited by this paper
• Decreased BDNF signalling in transgenic mice reduces epileptogenesis

  2002cited by this paper
• Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.

  2002cited by this paper
• Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF.

  2002cited by this paper
• Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease.

  2001cited by this paper
• Neuroprotection through Delivery of Glial Cell Line-Derived Neurotrophic Factor by Neural Stem Cells in a Mouse Model of Parkinson's Disease

  2001cited by this paper
• GDNF reverses priming for dyskinesia in MPTP‐treated, l‐DOPA‐primed common marmosets

  2001cited by this paper
• Neurotrophins: roles in neuronal development and function.

  2001cited by this paper
• Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment.

  2001cited by this paper
• Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.

  2001cited by this paper
• Alpha-synuclein and neurodegenerative diseases

  2001cited by this paper
• Novel mechanism for age‐related macular degeneration: An equilibrium shift between the angiogenesis factors VEGF and PEDF

  2001cited by this paper
• Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System

  2000cited by this paper
• Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.

  2000cited by this paper
• Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

  2000cited by this paper
• A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis

  2000cited by this paper
• Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.

  2000cited by this paper
• Blood vessels change in the mesencephalon of patients with Parkinson's disease.

  1999cited by this paper
• Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

  1999cited by this paper
• Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.

  1999cited by this paper
• Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer.

  1999cited by this paper
• Caloric intake and aging: mechanisms in rodents and a study in nonhuman primates.

  1999cited by this paper
• Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease

  1999cited by this paper
• Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease.

  1999cited by this paper
• Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra.

  1999cited by this paper
• Blood vessels change in the mesencephalon of patients with Parkinson's disease.

  1999cited by this paper
• Vascular, glial and neuronal effects of vascular endothelial growth factor in mesencephalic explant cultures.

  1999cited by this paper
• Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and in vitro hyperexcitability in the hippocampus and entorhinal cortex.

  1999cited by this paper
• Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor.

  1998cited by this paper
• Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor

  1998cited by this paper
• Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons

  1998cited by this paper
• An immortalized, type-1 astrocyte of mescencephalic origin source of a dopaminergic neurotrophic factor

  1998cited by this paper
• Anti‐inflammatory effects of granulocyte colony‐stimulating factor

  1998cited by this paper
• Behavioral and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats.

  1997cited by this paper
• Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.

  1997cited by this paper

• Understanding the Blood-Brain Barrier: From Physiology to Pathology.

  2025cites this paper
• Neuroprotective Effects of Neurotrophic Factors in Neurodegenerative Diseases: A Systematic Review

  2024cites this paper
• Cryogel microcarriers for sustained local delivery of growth factors to the brain.

  2024cites this paper
• The forensic aspects of suicide and neurotrophin factors: a research study

  2024cites this paper
• Dipeptide mimetic of BDNF ameliorates motor dysfunction and striatal apoptosis in 6-OHDA-induced Parkinson's rat model: Considering Akt and MAPKs signaling.

  2023cites this paper
• In vitro induction of in vivo-relevant stellate astrocytes in 3D brain-derived, decellularized extracellular matrices.

  2023cites this paper
• Restoring lost nigrostriatal fibers in Parkinson's disease based on clinically-inspired design criteria.

  2021cites this paper
• Cellular and molecular pathophysiology in the progression of Parkinson’s disease

  2021cites this paper
• Blood-Brain Barrier Overview: Structural and Functional Correlation

  2021cites this paper
• Neurotrophic Therapy for ALS/MND

  2021cites this paper
• Liver Growth Factor Induces Glia-Associated Neuroprotection in an In Vitro Model of Parkinson´s Disease

  2020cites this paper
• Overexpression of α-Synuclein Reorganises Growth Factor Profile of Human Astrocytes

  2020cites this paper
• Overexpression of α-Synuclein Reorganises Growth Factor Profile of Human Astrocytes

  2020cites this paper
• GDNF-expressing Macrophages Restore Motor Functions at a Severe Late-stage, and Produce Long-Term Neuroprotective Effects at an Early-stage of Parkinson's Disease in Transgenic Parkin Q311X(A) Mice.

  2019cites this paper
• Growth Factors in the Human Body: A Conceptual Update

  2019cites this paper
• Blood‐brain barrier (BBB) and the complement landscape

  2018cites this paper
• Astrocyte-Like Cells Differentiated from Dental Pulp Stem Cells Protect Dopaminergic Neurons Against 6-Hydroxydopamine Toxicity

  2018cites this paper
• Neurotrophic Factors: An Overview.

  2018cites this paper
• Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease

  2017cites this paper
• Potential Neuro-therapeutic Effect of Flaxseed Oil on the Striatum of Rotenone Mice Model of Parkinson’ Diseases

  2017cites this paper
• Growth and Neurotrophic Factors in HIV-Associated Neurocognitive Disorders

  2017cites this paper
• The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.

  2016cites this paper
• Novel Approaches in Astrocyte Protection: from Experimental Methods to Computational Approaches

  2016cites this paper
• Growth Factors and Astrocytes Metabolism: Possible Roles for Platelet Derived Growth Factor.

  2016cites this paper
• The Development of Treatment for Parkinson's Disease

  2015cites this paper
• Astrocytes: New Targets for the Treatment of Neurodegenerative Diseases.

  2015cites this paper
• GDNF-Transfected Macrophages Produce Potent Neuroprotective Effects in Parkinson's Disease Mouse Model

  2014cites this paper
• Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease

  2014influential citation
• Mildronate and its neuroregulatory mechanisms: targeting the mitochondria, neuroinflammation, and protein expression.

  2013cites this paper
• Cellular Uptake Mechanism and Therapeutic Utility of a Novel Peptide in Targeted-Delivery of Proteins into Neuronal Cells

  2013cites this paper
• Astrocytes Role in Parkinson: A Double-Edged Sword

  2013cites this paper
• The neurotrophin family of neurotrophic factors: an overview.

  2012cites this paper
• A 6-hydroxydopamine in vivo model of Parkinson's disease.

  2012cites this paper
• Cytokines as potential biomarkers for Parkinson's disease: a multiplex approach.

  2012cites this paper
• MANF regulates dopaminergic neuron development in larval zebrafish.

  2012cites this paper
• α-Synuclein and Neuronal Cell Death

  2012cites this paper
• Peptide mimetics of neurotrophins and their receptors.

  2011cites this paper
• Mildronate as a regulator of protein expression in a rat model of Parkinson's disease.

  2011cites this paper
• Connecting Parkinson's disease and drug addiction: common players reveal unexpected disease connections and novel therapeutic approaches.

  2011cites this paper
• Akt as a Victim, Villain and Potential Hero in Parkinson’s Disease Pathophysiology and Treatment

  2011cites this paper